Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) collectively exhibit efficacy in reducing both glucose levels and body weight, demonstrating a diminished risk of hypoglycemia; current KDIGO (Kidney Disease Improving Global Outcomes) and ADA (American Diabetes Association) guidelines prioritize this pharmacological class of antihyperglycemic drugs in the leading positions for the treatment of patients with T2DM and CKD [12]. The gene discussed is GLP1R; the disease is diabetes mellitus.